Jigarkumar Parikh

ORCID: 0000-0002-1450-087X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic and Hepatic Oncology Research
  • Cancer Immunotherapy and Biomarkers
  • Neuroendocrine Tumor Research Advances
  • Renal cell carcinoma treatment
  • Pancreatitis Pathology and Treatment
  • Cancer, Hypoxia, and Metabolism
  • Viral-associated cancers and disorders
  • Microscopic Colitis
  • Obesity and Health Practices
  • Prostate Cancer Diagnosis and Treatment
  • Polyomavirus and related diseases
  • Health Promotion and Cardiovascular Prevention
  • Nutrition and Health in Aging
  • Bone and Joint Diseases
  • Ferroptosis and cancer prognosis
  • Tumors and Oncological Cases
  • Blood groups and transfusion
  • Neuroblastoma Research and Treatments
  • Ocular Oncology and Treatments
  • Lung Cancer Research Studies
  • Lymphoma Diagnosis and Treatment
  • Urologic and reproductive health conditions
  • Prostate Cancer Treatment and Research
  • Liver Diseases and Immunity
  • Renal and related cancers

Augusta University Health
2013-2025

National Cancer Center of Georgia
2019-2022

Augusta University
2009-2020

Palmetto Hematology Oncology
2017

Ascension Providence Hospital
2017

315 Background: Socioeconomic position (SEP) is a key social determinant of health (SDOH) associated with disparities in cancer care and cardiovascular (CV) outcomes patients prostate (PC). Understanding the impact SEP on critical for addressing inequities PC CV outcomes. Methods: We conducted retrospective cohort study SEER-Medicare database. Multiple were assessed ≥65 years age no prior disease localized or advanced PC. was defined using census-tract level Yost index where those living...

10.1200/jco.2025.43.5_suppl.315 article EN Journal of Clinical Oncology 2025-02-10

<h3>Background</h3> Renal medullary carcinoma is one of the rarest malignancies arising from kidney. Despite various aggressive therapeutic regimens, mortality remains significantly high (95%) with a median overall survival 5&nbsp;months. Furthermore, scarcity this malignancy renders randomized clinical trials impossible. We examined expression programmed death ligand 1 (PD-L1) in two new renal cases, investigated their responses to PD-L1 inhibitor nivolumab and explored predictive role rate...

10.1186/s40425-017-0267-9 article EN cc-by Journal for ImmunoTherapy of Cancer 2017-07-24

Xp11.2 translocation renal cell carcinomas (TRCCs) are a rare family of tumors newly recognized by the World Health Organization (WHO) in 2004. These result fusion partner genes to TFE3 gene located on Xp11.2. They most common pediatric population, but have been recently implicated adult carcinoma (RCC) presenting at an early age. TFE3-mediated direct transcriptional upregulation Met tyrosine kinase receptor triggers dramatic activation downstream signaling pathways including protein B...

10.4081/rt.2009.e53 article EN cc-by-nc Rare Tumors 2009-12-01

The emergence of immune checkpoint inhibitors has transformed treatment paradigms for various malignancies. Patients with cancer are at increased risk complications and hospitalizations from influenza; therefore, it is recommended that they receive inactivated influenza vaccination. However, efficacy safety vaccination in patients receiving uncertain. objective this prospective case series was to evaluate the incidence immune-mediated adverse events (imAEs) following inhibitors. Changes...

10.1177/1078155219868758 article EN Journal of Oncology Pharmacy Practice 2019-08-31

Choroid plexus carcinomas (CPCs) are rare epithelial central nervous system tumors. CPC occurs mainly in infants and young children, comprising ∼1 to 4% of all pediatric brain neoplasms. There is very limited information available regarding tumor biology treatment due its rarity. have been various case reports meta-analyses reported cases with CPC. Surgical resection often challenging but remains a well-established option. Chemotherapy reserved for recurrent or refractory cases, the goal...

10.1055/s-0032-1333419 article EN Journal of Neurological Surgery Part A Central European Neurosurgery 2013-02-20

TPS682 Background: Glutamine metabolism is upregulated in renal cell carcinoma (RCC) and important for RCC tumor proliferation survival. CB-839 a first-in-clinic, potent, oral inhibitor of the mitochondrial enzyme glutaminase (GLS), which controls critical step glutamine. demonstrated synergistic anti-tumor activity when combined with cabozantinib, VEGFR2/MET/AXL inhibitor, preclinical models. In phase 1 study cohort, plus cabozantinib as 2L+ therapy showed encouraging safety efficacy...

10.1200/jco.2019.37.7_suppl.tps682 article EN Journal of Clinical Oncology 2019-03-01

Adrenal cortical carcinosarcomas are a rare and typically aggressive malignancy with few reported cases in medical literature. We present case of 78-year-old female who presented complaints fatigue right shoulder pain. Imaging the abdomen computed tomography visualized large mass upper quadrant. The was radiologically described as 22 × 17 13 cm heterogeneous its epicenter area adrenal gland, medial peripheral effacement all structures Non-contrasted images demonstrated anterior mid-portion...

10.3390/diagnostics12102419 article EN cc-by Diagnostics 2022-10-06

e23026 Background: The treatment of salivary gland tumors has not changed significantly in the past two decades. However, its increased incidence geriatric population poses new challenges for their management. This study explores incidence-based mortality (IBM) trends and non-geriatric time period 2000 to 2014 compares between races. Methods: Mortality data was extracted from Surveillance, Epidemiology, End Results (SEER) Database years 2014. IBM all stages queried results were grouped by...

10.1200/jco.2019.37.15_suppl.e23026 article EN Journal of Clinical Oncology 2019-05-20

10.1016/s0090-4295(21)00307-1 article EN Urology 2021-05-01
Coming Soon ...